Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 7/20 | 0.35 |
| ▸ | MMP9 | P14780 | 6/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462974 | 0.85 | ITGB3 (0.38) | ALDH1A1TYMSMAPTTDP1POLB | |
| SCHEMBL4557815 | 0.83 | ITGB3 (0.42) | ALDH1A1ITGB3ITGA2B | |
| SCHEMBL4459041 | 0.81 | ITGB3 (0.36) | ITGB3ITGA2BHTTITGAV | |
| SCHEMBL4450993 | 0.81 | ADAMTS4 (0.44) | ALDH1A1TYMSMAPTPOLBMMP2 | |
| SCHEMBL4452656 | 0.75 | PKM (0.35) | PKM | |
| SCHEMBL4452679 | 0.74 | CTSB (0.32) | ALDH1A1MAPTITGB3ITGA2BADAMTS4 | |
| SCHEMBL3747259 | 0.72 | F10 (0.58) | — | |
| SCHEMBL4556596 | 0.69 | PLAU (0.41) | ITGB3ITGA2B | |
| SCHEMBL4365696 | 0.69 | CA2 (0.51) | ALDH1A1TYMSMAPTTDP1POLB | |
| SCHEMBL4516502 | 0.66 | TDP1 (0.61) | ALDH1A1MAPTTDP1POLBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | PLAU, PLAUR, ENPEP | ALDH1A1 1671/4885TYMS 700/4885MAPT 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.